PURPOSE: The treatment of metastatic colorectal carcinoma represents a major clinical challenge. We investigated the hypothesis that the desmoplastic reaction within the liver elicited by metastatic adenocarcinoma, characterized by collagen I deposition and altered collagen IV distribution, promotes the growth and survival of hepatic colorectal carcinoma metastases. EXPERIMENTAL DESIGN: Partial hepatectomy specimens for metastatic colorectal adenocarcinoma were examined immunohistochemically for differential integrin expression. Human colorectal adenocarcinoma cell lines HT-29, KM12SM, and KM12c were grown on wild-type collagen I or IV, or cleavage-resistant r/r collagen I, and assessed for their growth, survival, and resistance to 5-fluorouracil. The effect of alpha(v)beta(3) and alpha(v)beta(5) integrin blockade by neutralizing antibodies was examined. RESULTS: Collagen I, in contrast to collagen IV, significantly enhanced the growth, survival, and chemoresistance of colorectal carcinoma cells. Blockade of the alpha(v)beta(3) and alpha(v)beta(5) integrins significantly reduced colorectal carcinoma cell proliferation on collagen, especially in the cell line with the most metastatic potential. These in vitro findings correlated with the pattern of integrin expression identified within resected hepatic colorectal carcinoma metastases. Using matrix metalloproteinase-resistant r/r collagen I as a dominant negative ligand for alpha(v) integrins, we showed a key role for this integrin-ligand interaction in mediating the survival and proliferation of colorectal carcinoma cells. CONCLUSIONS: Desmoplasia has an important role in the development of hepatic colorectal carcinoma metastasis. The interaction between integrin and collagen I is identified as a potential therapeutic target.
PURPOSE: The treatment of metastatic colorectal carcinoma represents a major clinical challenge. We investigated the hypothesis that the desmoplastic reaction within the liver elicited by metastatic adenocarcinoma, characterized by collagen I deposition and altered collagen IV distribution, promotes the growth and survival of hepatic colorectal carcinoma metastases. EXPERIMENTAL DESIGN: Partial hepatectomy specimens for metastatic colorectal adenocarcinoma were examined immunohistochemically for differential integrin expression. Human colorectal adenocarcinoma cell lines HT-29, KM12SM, and KM12c were grown on wild-type collagen I or IV, or cleavage-resistant r/r collagen I, and assessed for their growth, survival, and resistance to 5-fluorouracil. The effect of alpha(v)beta(3) and alpha(v)beta(5) integrin blockade by neutralizing antibodies was examined. RESULTS: Collagen I, in contrast to collagen IV, significantly enhanced the growth, survival, and chemoresistance of colorectal carcinoma cells. Blockade of the alpha(v)beta(3) and alpha(v)beta(5) integrins significantly reduced colorectal carcinoma cell proliferation on collagen, especially in the cell line with the most metastatic potential. These in vitro findings correlated with the pattern of integrin expression identified within resected hepatic colorectal carcinoma metastases. Using matrix metalloproteinase-resistant r/r collagen I as a dominant negative ligand for alpha(v) integrins, we showed a key role for this integrin-ligand interaction in mediating the survival and proliferation of colorectal carcinoma cells. CONCLUSIONS: Desmoplasia has an important role in the development of hepatic colorectal carcinoma metastasis. The interaction between integrin and collagen I is identified as a potential therapeutic target.
Authors: K P McHugh; K Hodivala-Dilke; M H Zheng; N Namba; J Lam; D Novack; X Feng; F P Ross; R O Hynes; S L Teitelbaum Journal: J Clin Invest Date: 2000-02 Impact factor: 14.808
Authors: C C Kumar; M Malkowski; Z Yin; E Tanghetti; B Yaremko; T Nechuta; J Varner; M Liu; E M Smith; B Neustadt; M Presta; L Armstrong Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: J Xu; D Rodriguez; E Petitclerc; J J Kim; M Hangai; Y S Moon; G E Davis; P C Brooks; S M Yuen Journal: J Cell Biol Date: 2001-09-03 Impact factor: 10.539
Authors: Jörg Schrader; Timothy T Gordon-Walker; Rebecca L Aucott; Mariëlle van Deemter; Alexander Quaas; Shaun Walsh; Daniel Benten; Stuart J Forbes; Rebecca G Wells; John P Iredale Journal: Hepatology Date: 2011-04 Impact factor: 17.425
Authors: Vivian Barry-Hamilton; Rhyannon Spangler; Derek Marshall; Scott McCauley; Hector M Rodriguez; Miho Oyasu; Amanda Mikels; Maria Vaysberg; Haben Ghermazien; Carol Wai; Carlos A Garcia; Arleene C Velayo; Brett Jorgensen; Donna Biermann; Daniel Tsai; Jennifer Green; Shelly Zaffryar-Eilot; Alison Holzer; Scott Ogg; Dung Thai; Gera Neufeld; Peter Van Vlasselaer; Victoria Smith Journal: Nat Med Date: 2010-09-05 Impact factor: 53.440
Authors: P Bohanes; D Yang; F Loupakis; M J LaBonte; A Gerger; Y Ning; C Lenz; F Lenz; T Wakatsuki; W Zhang; L Benhaim; A El-Khoueiry; R El-Khoueiry; H-J Lenz Journal: Pharmacogenomics J Date: 2014-12-09 Impact factor: 3.550
Authors: Sergio Lavilla-Alonso; Gerd Bauerschmitz; Usama Abo-Ramadan; Juha Halavaara; Sophie Escutenaire; Iulia Diaconu; Turgut Tatlisumak; Anna Kanerva; Akseli Hemminki; Sari Pesonen Journal: J Transl Med Date: 2010-08-23 Impact factor: 5.531
Authors: Nikolaos Vassos; Tilman Rau; Susanne Merkel; Fabian Feiersinger; Carol I Geppert; Michael Stürzl; Werner Hohenberger; Roland S Croner Journal: Int J Clin Exp Pathol Date: 2013-12-15